Peripheral T-Cell Lymphomas (PTCL) Pipeline Summary

DelveInsight’s, “Peripheral T-Cell Lymphomas (PTCL) - Pipeline Insight, 2026” report provides comprehensive insights about 30+ companies and 32+ pipeline drugs in Peripheral T-Cell Lymphomas (PTCL) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Peripheral T-Cell Lymphomas (PTCL): Understanding

Peripheral T-Cell Lymphomas (PTCL): Overview

Peripheral T-cell lymphomas (PTCLs) are a rare and heterogeneous group of aggressive non-Hodgkin lymphomas arising from mature, post-thymic T cells or, in some entities, natural killer (NK) cells. More than 30 distinct entities are recognized across nodal, extranodal, leukemic and cutaneous categories, including PTCL-not otherwise specified (PTCL-NOS), angioimmunoblastic/T-follicular helper (TFH) lymphomas and anaplastic large-cell lymphoma (ALCL). PTCLs generally have an aggressive clinical course and are frequently diagnosed at an advanced stage. They account for approximately 10–15% of non-Hodgkin lymphomas, although their incidence varies geographically.

Clinical manifestations vary according to the PTCL subtype and sites of involvement, but commonly include painless lymphadenopathy, fever, drenching night sweats, unexplained weight loss, fatigue and reduced appetite. Patients may also develop hepatosplenomegaly, edema, skin rashes or pruritus, while extranodal disease can produce gastrointestinal symptoms such as abdominal discomfort, nausea or diarrhea. Bone marrow involvement may result in cytopenias and constitutional symptoms can reflect systemic inflammatory activity. Because PTCLs can involve lymph nodes as well as the liver, spleen, skin, gastrointestinal tract and other organs, presentations are often clinically diverse.

The precise causes of PTCL remain incompletely understood, and most cases cannot be attributed to a single established risk factor. Disease development is driven by genetic and epigenetic abnormalities that disrupt normal T-cell differentiation, activation, proliferation and survival, with contributions from the tumor microenvironment and, in selected entities, viral infection. Aberrant T-cell receptor (TCR), PI3K–AKT, JAK–STAT and NF-?B signaling, together with alterations in epigenetic regulators, can promote persistent proliferation and resistance to cell death. These molecular abnormalities allow abnormal T-cell clones to evade normal immune regulation and progressively accumulate, producing lymphoma.

Diagnosis requires an integrated assessment of clinical findings, imaging, tissue morphology, immunophenotyping and molecular characteristics, with an adequate lymph-node or involved-tissue biopsy being central to establishing the specific PTCL subtype. Immunohistochemistry and flow cytometry help determine the T-cell phenotype and expression of markers such as CD2, CD3, CD4, CD5, CD7 and CD30, while molecular testing can assess T-cell receptor clonality and recurrent genetic alterations. PET/CT and bone-marrow evaluation are used for staging and assessment of disease extent. Treatment is subtype- and stage-dependent and may include combination chemotherapy, often followed by autologous stem-cell transplantation in eligible patients, while CD30-directed therapy, other targeted or immunotherapies, radiation and clinical trials provide additional options; newer approaches increasingly aim to exploit the molecular and epigenetic vulnerabilities of individual PTCL subtypes.

“Peripheral T-Cell Lymphomas (PTCL) - Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Peripheral T-Cell Lymphomas (PTCL) pipeline landscape is provided which includes the disease overview and Peripheral T-Cell Lymphomas (PTCL) treatment guidelines. The assessment part of the report embraces, in depth Peripheral T-Cell Lymphomas (PTCL) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Peripheral T-Cell Lymphomas (PTCL) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Peripheral T-Cell Lymphomas (PTCL) R&D. The therapies under development are focused on novel approaches to treat/improve Peripheral T-Cell Lymphomas (PTCL).

Peripheral T-Cell Lymphomas (PTCL) Emerging Drugs Chapters

This segment of the Peripheral T-Cell Lymphomas (PTCL) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Peripheral T-Cell Lymphomas (PTCL) Emerging Drugs

XNW5004: Evopoint Biosciences

XNW5004 is an investigational, orally administered selective EZH2 inhibitor developed by Evopoint Biosciences, designed to inhibit both wild-type and mutant EZH2 and suppress H3K27 trimethylation, thereby promoting cell-cycle arrest and apoptosis in tumor cells. In September 2024, it received Breakthrough Therapy Designation (BTD) from China’s CDE for relapsed/refractory (R/R) PTCL based on clinical data demonstrating promising activity. In a Phase I/II study, XNW5004 achieved an ORR of 70.3% in PTCL at the 1,200 mg BID dose, with median PFS of 15.7 months and median duration of response of 13.9 months. Currently, the drug is in Phase III study evaluating XNW5004 versus chidamide in R/R PTCL.

BR101801: Boryung Pharmaceutical

BR101801 (bosmolisib) is an oral, investigational triple inhibitor of PI3K-?, PI3K-? and DNA-PK being developed by Boryung Pharmaceutical for relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL). By simultaneously inhibiting PI3K signaling and DNA-PK, the drug is designed to suppress tumor-cell growth, induce cell-cycle arrest and apoptosis, and reduce the stability of oncogenic c-Myc. In an earlier Phase I study, BR101801 demonstrated an ORR of 31.6% and a complete response rate of 21.1% in evaluable R/R PTCL patients, supporting further development. The Phase II study is designed to evaluate BR101801 monotherapy in patients with R/R PTCL with 200 mg once daily being the established recommended Phase II dose.

FG-M131: FutureGen Biopharmaceutical

FG-M131 is an investigational antibody–drug conjugate (ADC) targeting T-cell receptor beta constant region 1 (TRBC1), a component of the ?? T-cell receptor complex. By selectively targeting TRBC1-positive malignant T cells while potentially sparing TRBC2-positive normal T cells, it represents a novel targeted approach for T-cell malignancies. The drug is being evaluated in a multicenter, open-label Phase I/II study in patients with TRBC1-positive relapsed/refractory PTCL, assessing safety, pharmacokinetics and preliminary antitumor activity.

KK2223: Kyowa Kirin

KK2223 is an investigational, first-in-class therapeutic developed by Kyowa Kirin for T-cell non-Hodgkin lymphomas, including relapsed/refractory PTCL and CTCL. It is being evaluated in a first-in-human, Phase I, open-label, multicenter study, evaluating intravenous KK2223 through dose-escalation and backfill cohorts. The trial is designed to assess safety, tolerability, pharmacokinetics and pharmacodynamics in patients with relapsed/refractory PTCL or CTCL. The study includes PTCL subtypes such as PTCL-NOS, nodal TFH lymphoma and ALCL, positioning KK2223 as an emerging investigational option for heavily pretreated T-cell malignancies.

Further product details are provided in the report……..

Peripheral T-Cell Lymphomas (PTCL): Therapeutic Assessment

This segment of the report provides insights about the different Peripheral T-Cell Lymphomas (PTCL) drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Peripheral T-Cell Lymphomas (PTCL)

There are approx. 30+ key companies which are developing the therapies for Peripheral T-Cell Lymphomas (PTCL). The companies which have their Peripheral T-Cell Lymphomas (PTCL) drug candidates in the most advanced stage, i.e. Phase III include Evopoint Biosciences.

Phases

DelveInsight’s report covers around 32+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Peripheral T-Cell Lymphomas (PTCL) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Peripheral T-Cell Lymphomas (PTCL): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Peripheral T-Cell Lymphomas (PTCL) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Peripheral T-Cell Lymphomas (PTCL) drugs.

Peripheral T-Cell Lymphomas (PTCL) Report Insights

• Peripheral T-Cell Lymphomas (PTCL) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Peripheral T-Cell Lymphomas (PTCL) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Peripheral T-Cell Lymphomas (PTCL) drugs?
• How many Peripheral T-Cell Lymphomas (PTCL) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Peripheral T-Cell Lymphomas (PTCL)?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Peripheral T-Cell Lymphomas (PTCL) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Peripheral T-Cell Lymphomas (PTCL) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Evopoint Biosciences
• Boryung Pharmaceutical
• FutureGen Biopharmaceutical
• Kyowa Kirin
• Tarapeutics Science
• Boston Immune Technologies and Therapeutics
• Corvus Pharmaceuticals, Inc.
• SciTech Development, Inc.
• HaiHe Biopharma
• AstraZeneca
• Shanghai Yingli Pharmaceutical
• Secura Bio
• Innate Pharma
• iOnctura
• Xenothera SAS

Key Products

• XNW5004
• BR101801
• FG-M131
• KK2223
• TR115
• BITR2101
• Soquelitinib
• Fenretinide
• HH2853
• AZD3470
• Linperlisib
• Duvelisib
• Lacutamab
• Roginolisib
• LIS1